IA Trial Radar | ||
|---|---|---|
L'essai clinique NCT07374692 pour Recurrent CNS Tumors, Cancer du cerveau, Gliomes, IDH-wildtype Gliomas, IDH-mutant Gliomas, Rare CNS Tumor est en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici. | ||
Institut national du cancer, États-UnisObservational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors 80 Observationnel
Primary central nervous system (CNS) tumors grow in the brain and spinal cord. These tumors are rare, but they are difficult to treat and often fatal. SmartMatch is a new technology that tries to help find the best medicines for the particular tumor by testing how small pieces of surgically removed tumor tissue react to different drugs. The study team wants to see if SmartMatch can complete the analysis ...
Afficher plusBackground:
- Primary central nervous system (CNS) tumors are uncommon and are mostly classified as rare diseases. Despite their low incidence, CNS cancers are associated with significant morbidity and mortality across all age groups.
- Treatment options for CNS tumors are limited, especially upon disease progression, largely due to the incomplete understanding of disease biology and the challenges in conducting cli...
Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors
- 10002539
- 002539-C
Brain Tumor
Rare Tumor
SmartMatch
Gliomas
Drug Screen
| Groupe de participants/Bras | Intervention/Traitement |
|---|---|
Autre1/SmartMatch testing Turnaround time for SmartMatch platform implementation and molecular profiling of recurrent CNS tumors | Tumor sample collection Fresh tumor samples will be collected for the study only if available following a planned biopsy or resection performed at NIH. |
| Critères d'évaluation | Description de la mesure | Période |
|---|---|---|
To determine the proportion of participants with advanced CNS tumors for whom SmartMatch drug screen analysis results are generated within 21 days from the time of tumor tissue acquisition | Point estimates and 95% exact confidence intervals will be calculated using the Clopper-Pearson method | 21 days from the time of tumor tissue acquisition |
| Critères d'évaluation | Description de la mesure | Période |
|---|---|---|
To perform molecular profiling of advanced CNS tumors at disease progression. | Descriptive statistics will be used to summarize the molecular profiling results | End of Study |
Participants must have advanced CNS tumors confirmed by a documented pathology report, including:
- recurrent isocitrate dehydrogenase (IDH)-wild-type high-grade glioma
- recurrent IDH-mutant gliomas
- other recurrent CNS tumors
Participants must have been scheduled for a brain tumor biopsy or resection. Note: Scheduled brain tumor biopsy or resection must be at least 6 months after any previous radiation therapy, if applicable. All procedures are planned to take place at NIH.
Age >= 15 years.
Ability of participant, parent/guardian, or Legally Authorized Representative (LAR) to understand and sign a written informed consent document.
Institut national du cancer, États-UnisMaryland